Simon Rule, MD, PhD

Simon Rule, MD, PhD, shares his thoughts on the FDA’s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.

Simon Rule, MD, PhD, discusses the current treatment approaches for patients with mantle cell lymphoma in both the United Kingdom and the United States. He says treatment strategies are pretty well established on both sides of the Atlantic Ocean.

Simon Rule, MD, PhD, shares his treatment considerations for select patients with mantle cell lymphoma.